|
|
Article: Availability of additional trivalent inactivated influenza vaccine for adults (Afluria[R]).(Notice to Readers)(Brief article)
- Article from:
- MMWR. Morbidity and Mortality Weekly Report
- Article date:
- November 23, 2007
CopyrightCOPYRIGHT 2007 U.S. Government Printing Office. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
On September 28, 2007, CSL Biotherapies, Inc., (King of Prussia, Pennsylvania) received approval from the Food and Drug Administration for use of Afluria[R], a trivalent inactivated influenza vaccine (TIV) administered intramuscularly in persons aged [greater than or equal to] 18 years (1). Afluria can be used for any adult influenza vaccine indication (2).
The addition of Afluria brings to six (five TIVs and one live, attenuated influenza vaccine) the number of seasonal influenza vaccines licensed for the U.S. market. CDC estimates that manufacturers of the six vaccines will supply a record 132 million doses of influenza vaccine for the 2007-08 influenza season.
...